Atara Biotherapeutics, Inc. (NASDAQ:ATRA) CAO Yanina Grant-Huerta Sells 2,218 Shares

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) CAO Yanina Grant-Huerta sold 2,218 shares of the company’s stock in a transaction dated Friday, May 16th. The stock was sold at an average price of $6.76, for a total transaction of $14,993.68. Following the completion of the sale, the chief accounting officer now owns 37,067 shares in the company, valued at approximately $250,572.92. This trade represents a 5.65% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Atara Biotherapeutics Price Performance

Shares of Atara Biotherapeutics stock traded up $0.27 during trading on Tuesday, reaching $7.00. 75,613 shares of the stock traded hands, compared to its average volume of 124,406. The company has a market capitalization of $41.73 million, a price-to-earnings ratio of -0.27 and a beta of 0.30. Atara Biotherapeutics, Inc. has a 52-week low of $5.01 and a 52-week high of $18.71. The business has a fifty day simple moving average of $6.65 and a two-hundred day simple moving average of $9.15.

Atara Biotherapeutics (NASDAQ:ATRA) last issued its quarterly earnings data on Thursday, May 15th. The biotechnology company reported $3.50 EPS for the quarter, topping analysts’ consensus estimates of ($3.07) by $6.57. The business had revenue of $98.10 million during the quarter, compared to analysts’ expectations of $4.30 million. On average, research analysts predict that Atara Biotherapeutics, Inc. will post -10.39 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of analysts have weighed in on ATRA shares. HC Wainwright restated a “neutral” rating on shares of Atara Biotherapeutics in a research note on Tuesday, January 28th. Canaccord Genuity Group reiterated a “buy” rating and set a $17.00 price target on shares of Atara Biotherapeutics in a report on Tuesday, March 11th. Finally, RODMAN&RENSHAW lowered shares of Atara Biotherapeutics from a “strong-buy” rating to a “hold” rating in a report on Tuesday, January 21st. One investment analyst has rated the stock with a sell rating, three have given a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $17.75.

Institutional Investors Weigh In On Atara Biotherapeutics

Several hedge funds and other institutional investors have recently modified their holdings of ATRA. Point72 Asia Singapore Pte. Ltd. bought a new position in Atara Biotherapeutics in the fourth quarter worth approximately $48,000. Northern Trust Corp bought a new position in shares of Atara Biotherapeutics during the 4th quarter worth $149,000. Cubist Systematic Strategies LLC purchased a new position in shares of Atara Biotherapeutics during the fourth quarter valued at $169,000. Birchview Capital LP purchased a new position in Atara Biotherapeutics during the 4th quarter valued at about $293,000. Finally, Marshall Wace LLP bought a new stake in shares of Atara Biotherapeutics in the 4th quarter valued at about $332,000. 70.90% of the stock is currently owned by hedge funds and other institutional investors.

About Atara Biotherapeutics

Atara Biotherapeutics, Inc engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma.